ArticleMolecular medicine (Cambridge, Mass.)
Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.
Article in Molecular medicine (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Plasma Macrophage Migration Inhibitory Factor as a Biomarker of Thromboinflammatory Dysregulation in Anti-Neutrophil Cytoplasmic Antibody- Associated Vasculitis.Archives of rheumatology · 2026Article
- Urinary macrophage migration inhibitory factor predicts kidney failure in advanced CKD patients.BMC nephrology · 2026Article
- MIF Regulates the Th17/Treg Ratio to Exacerbate Kidney Injury in Chronic Kidney Disease.Inflammation · 2025Article
- Chicago Sky Blue 6B modulates MAPK/NF-kB pathway in rat knee osteoarthritis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- The multifaced role of the macrophage migration inhibitory factor family in organ fibrosis.American journal of physiology. Cell physiology · 2025Review
- Macrophage-derived macrophage migration inhibitory factor mediates renal injury in anti-glomerular basement membrane glomerulonephritis.Frontiers in immunology · 2024Article
- Role of the immune system in liver transplantation and its implications for therapeutic interventions.MedComm · 2023Review
- Macrophage Migration Inhibitory Factor (MIF) as a Stress Molecule in Renal Inflammation.International journal of molecular sciences · 2022Review
- Article
- Elevated concentrations of macrophage migration inhibitory factor in serum and cerebral microdialysate are associated with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.Frontiers in neurology · 2022Article
- Changes of Urinary Cytokines in Non-Diabetic Obese Patients After Laparoscopic Sleeve Gastrectomy.International journal of general medicine · 2021Article
- A pilot study on gene expression of endoplasmic reticulum unfolded protein response in chronic kidney disease.Biochemistry and biophysics reports · 2020Article
- TheJournal of clinical medicine · 2020Article
- MIF plasma level as a possible tool to predict steroid responsiveness in children with idiopathic nephrotic syndrome.European journal of clinical pharmacology · 2019Article
- Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis.International journal of molecular sciences · 2018Article
- Macrophage migration inhibitory factor (MIF) in the development and progression of pulmonary arterial hypertension.Global cardiology science & practice · 2018Review
- Tangshen formula improves inflammation in renal tissue of diabetic nephropathy through SIRT1/NF-κB pathway.Experimental and therapeutic medicine · 2018Article
- Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus.Lupus science & medicine · 2018Article
- Cytokine Signature in End-Stage Renal Disease Patients on Hemodialysis.Disease markers · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) carries an increased risk of cardiovascular disease (CVD). Macrophage migration inhibiting factor (MIF) is a proinflammatory cytokine implicated in the pathogenesis of sepsis, autoimmune disease, atherogenesis, and plaque instability, and is a known cardiac depressant. This post-hoc, cross-sectional study examined whether MIF serum concentrations are elevated in CKD patients. Our study included CKD 3-5 patients with moderate to severe renal dysfunction (n = 257) (mean age SD; 55 +/- 12 years) and 53 controls (60 +/- 12 years). Serum MIF concentrations, measured by enzyme-linked immunosorbent assay (ELISA), were studied in relation to glomerular filtration rate (GFR), presence of CVD, outcome and inflammatory and oxidative stress markers. MIF was significantly elevated in CKD patients compared with controls (CKD: median 676 [range 118-8275 pg/mL] controls: 433 [142-4707] pg/mL; P = 0.008). MIF was also associated with 8-hydroxy-2-deoxyguanosine (8-OH-dG) levels (rho = 0.26; P = 0.001), a marker of oxidative stress, and ICAM-1 levels (rho = 0.14; P = 0.02), a marker of endothelial activation. However, the elevated MIF concentrations were neither correlated with glomerular filtration rate (GFR) nor inflammatory markers such as CRP, IL-6, and TNF. When combining MIF and IL-6 as a marker of inflammation, a significant increase in risk for CVD was found, but when analyzing all-cause mortality, this did not differ significantly with regard to mortality from inflamed patients with low MIF levels. The data suggest that increased serum MIF levels found in CKD is not caused primarily by poor renal function, but is associated with markers of oxidative stress and endothelial activation and may play a role in vascular disease associated with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.